Home › RLT targets by cancer › Liver Cancer
Radioligand therapy · Liver Cancer

Radioligand Therapy Targets in Liver Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in liver cancer (including hepatocellular carcinoma (HCC)). 4,557 show detectable protein staining. Established and emerging radioligand targets expressed in liver cancer include EGFR, STEAP2, HER3 (ERBB3) and c-MET (MET). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own liver cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank liver cancer targets free

Established and emerging radioligand targets in liver cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in liver cancer:

TargetIHC in liver cancer% positiveInternalizes
EGFRHigh (0.88)100%yes
STEAP2High (0.83)100%—
HER3 (ERBB3)High (0.70)91%yes
c-MET (MET)High (0.60)100%yes
SSTR2High (0.56)92%yes
B7-H3 (CD276)Medium (0.44)83%—
TMEFF2Medium (0.39)67%—
ITGAVMedium (0.36)67%—
Nectin-4 (NECTIN4)Medium (0.27)70%no
Claudin 18.2 (CLDN18)Medium (0.22)22%uncertain
Mesothelin (MSLN)Medium (0.20)30%yes
HER2 (ERBB2)Low (0.19)58%yes
CEA (CEACAM5)Low (0.19)29%—
FAPLow (0.15)27%yes
TROP2 (TACSTD2)Low (0.06)9%uncertain
CAIX (CA9)Low (0.06)9%no
CD19Low (0.03)10%—
CD38Low (0.03)9%—
ITGB6Low (0.03)8%—

Top cell-surface targets for liver cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in liver cancer% positiveInternalizesClinical stage
1EGFR
epidermal growth factor receptor
High (0.88)100%yesFDA-Approved
2IGF1R
insulin like growth factor 1 receptor
High (0.85)100%yesFDA-Approved
3S1PR1
sphingosine-1-phosphate receptor 1
High (0.61)100%yesFDA-Approved
4NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.89)100%uncertainFDA-Approved
5c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.60)100%yesFDA-Approved
6AMFR
autocrine motility factor receptor
High (1.00)100%yesDiscovery
7GPR139
G protein-coupled receptor 139
High (1.00)100%yesDiscovery
8LIFR
LIF receptor subunit alpha
High (0.97)100%yesDiscovery
9IL1R2
interleukin 1 receptor type 2
High (0.81)100%yesDiscovery
10CYSLTR2
cysteinyl leukotriene receptor 2
High (0.81)100%yesDiscovery
11HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.70)91%yesFDA-Approved
12MST1R
macrophage stimulating 1 receptor
High (0.67)100%yesFDA-Approved
13CHRM2
cholinergic receptor muscarinic 2
High (0.89)100%uncertainFDA-Approved
14CCRL2
C-C motif chemokine receptor like 2
High (0.75)100%yesDiscovery
15FLT4
fms related receptor tyrosine kinase 4
Medium (0.47)92%yesFDA-Approved
16MAOB
monoamine oxidase B
High (0.89)100%—FDA-Approved
17NOTCH1
notch receptor 1
High (0.67)100%yesClinical
18FZD6
frizzled class receptor 6
High (0.86)100%yesDiscovery
19EPHB2
EPH receptor B2
High (0.67)100%uncertainFDA-Approved
20SSTR2
somatostatin receptor 2
High (0.56)92%yesFDA-Approved
21FZD3
frizzled class receptor 3
High (0.81)100%yesDiscovery
22HTR6
5-hydroxytryptamine receptor 6
Medium (0.46)100%yesFDA-Approved
23M6PR
mannose-6-phosphate receptor, cation dependent
High (0.81)100%yesDiscovery
24IRAK4
interleukin 1 receptor associated kinase 4
High (0.64)100%yesClinical
25CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.61)100%yesClinical

Internalizing receptors in liver cancer

Targets expressed in liver cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

EGFR · IGF1R · S1PR1 · c-MET (MET) · AMFR · GPR139 · LIFR · IL1R2 · CYSLTR2 · HER3 (ERBB3) · MST1R · CCRL2

Liver Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in liver cancer. Clinical precedent lowers development risk but usually means more competition:

EGFR · IGF1R · S1PR1 · NR3C2 · c-MET (MET) · HER3 (ERBB3) · MST1R · CHRM2 · FLT4 · MAOB · NOTCH1 · EPHB2

How these liver cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in liver cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank liver cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free liver cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist liver cancer targets for your program · 5 free analyses, no card Rank liver cancer targets free